<DOC>
	<DOCNO>NCT00365820</DOCNO>
	<brief_summary>This study evaluate efficacy safety tegaserod opioid-induced constipation patient non-cancer pain .</brief_summary>
	<brief_title>Efficacy Safety Tegaserod Opioid-induced Constipation Patients With Non-cancer Pain</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>1 . Male female outpatient 18 year age old . 2 . Patients chronic noncancer pain necessitates use noninjectable opioid analgesic . The equivalent dose 300 mg morphine per day maximum opioid analgesic dose allow . In general , patient use opioids daily basis . 3 . Chronic pain present minimum 3 month need chronic use opioids pain relief . 4 . Constipation , accord investigator 's clinical judgment , result opioid use noncancer chronic pain . Opioidinduced constipation ( OIC ) define follow : less 3 spontaneous bowel movement per week least one follow least 25 % occasion : 1. hard hard stool 2. sensation incomplete evacuation 3. strain bowel movement 1 . Patients receive opioids abdominal pain connective tissue disorder . 2 . Planned discontinuation increase decrease 30 % current opioid dose 3 . Patients underwent major surgery within 3 month prior screen . 4 . Patients history prior chronic constipation ( CC ) present three month relate opioid use . 5 . Patients current diagnosis irritable bowel syndrome ( IBS ) constipation predominant alternator . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Opioid , constipation , tegaserod</keyword>
	<keyword>Opioid-induced constipation</keyword>
</DOC>